Brigitte Widemann

Congratulations to Brigitte Widemann, MD, for being named a Top Ten Clinical Research Achievement Awardee by the Clinical Research Forum and receiving a Distinguished Clinical Research Achievement Award for her study “Selumetinib in Children with Inoperable Plexiform Neurofibromas.”

Dr. Widemann is also National Cancer Institute Liaison to the SARC Board of Directors and Co-Principal Investigator of SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors. We are honored to work with Dr. Widemann, representative of the distinguished community of investigators dedicated to making progress in rare diseases including sarcomas.